DAFAR PUSTAKA

AJCC cancer staging manual 8th Edition. New York: springer, 2018.

Ahn, S., Woo, J. W., Lee, K., & Park, S. Y. (2020). HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. *Journal of pathology and translational medicine*, *54*(1), 34-44.

Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., ... & Wolff, A. C. (2020). Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update.

Ali, E. M., Ahmed, A. R., & Ali, A. M. (2014). Correlation of breast cancer subtypes based on ER, PR and HER2 expression with axillary lymph node status. *Cancer and Oncology Research*, *2*(4), 51-57.

AL, A. (2008). The Effect of Neoadjuvant Chemotherapy on Histologic Grade, Hormone Receptor Status, and Her2/neu Status in Breast Carcinoma. *The Breast Journal*, *14*, 16-21.

Al-Saleh, K., Salah, T., Arafah, M., Husain, S., Al-Rikabi, A., & Abd El-Aziz, N. (2021). Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia. *PLoS One*, *16*(3), e0247802.

Anwar, S. L., Raharjo, C. A., Herviastuti, R., Dwianingsih, E. K., Setyoheriyanto, D., Avanti, W. S., ... & Wulaningsih, W. (2019). Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: a hospital-based study. *BMC Women's Health*, *19*, 1-8.

Aronica, S. M., Kraus, W. L., & Katzenellenbogen, B. S. (1994). Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. *Proceedings of the National Academy of Sciences*, *91*(18), 8517-8521.

Barnes, C. J., & Kumar, R. (2004). Biology of the epidermal growth factor receptor family. *Molecular Targeting and Signal Transduction*, 1-13.

Bazley, L. A., & Gullick, W. J. (2005). The epidermal growth factor receptor family. *Endocrine-related cancer*, *12*(Supplement_1), S17-S27.

Beth A. Virnig, Tatyana Shamliyan, Todd M Tuttle, Robert L Kane, Timothy J Wilt (2009). Diagnosis and Management of Ductal Carcinoma in Situ (DCIS). AHRQ Publication; No. 09-E018.

Bevers, Therese B., et al. NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023: Featured Updates to the NCCN Guidelines. *Journal of the National Comprehensive Cancer Network*, 2023, 21.9: 900-909.

Bines, J., Oleske, D. M., & Cobleigh, M. A. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. *Journal of Clinical Oncology*, *14*(5), 1718-1729.

Bjornstrom, L., & Sjoberg, M. (2005). Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. *Molecular endocrinology*, *19*(4), 833-842.

Björnström, L., & Sjöberg, M. (2002). Mutations in the estrogen receptor DNA-binding domain discriminate between the classical mechanism of action and cross-talk with Stat5b and activating protein 1 (AP-1). *Journal of Biological Chemistry*, *277*(50), 48479-48483.

Brogi, Edi and Hannah Yong Wen. (2014). Special Subtypes of Breast Carcinoma: Tubular Carcinoma Low Grade Adenosquamous Carcinoma Invasive Micropapillary Carcinoma Mucinous Carcinoma. ASCP Session 1012, Special Subtypes of Breast Carcinoma, Oct 8th.

Burstein, Harold J. (2005) The distinctive nature of HER2-positive breast cancers. *New England Journal of Medicine*, 353.16: 1652-1654.

Citri, A., & Yarden, Y. (2006). EGF–ERBB signalling: towards the systems level. *Nature reviews Molecular cell biology*, *7*(7), 505-516.

Chang, E.C.; Frasor, J.; Komm, B.; Katzenellenbogen, B.S.(2006). Impact of Estrogen Receptor on Gene Networks Regulated by Estrogen Receptor in Breast Cancer Cells. Endocrinology, 147, 4831–4832.

Chen, S., Chen, C. M., Yu, K. D., Zhou, R. J., & Shao, Z. M. (2012). Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor–positive breast cancer. *Annals of surgical oncology*, *19*, 3002-3011.

Chung, Y. L., Sheu, M. L., Yang, S. C., Lin, C. H., & Yen, S. H. (2002). Resistance to tamoxifen-induced apoptosis is associated with direct interaction between

Her2/neu and cell membrane estrogen receptor in breast cancer. *International journal of cancer*, *97*(3), 306-312.

Chuthapisith S, Permsapaya W, Warnnissorn M, et al (2012). Breast cancer subtypes identified by the ER, PR and Her-2 status in Thai women. Asian Pac J Cancer Prev, 13, 459-62.

Colleoni, M., & Goldhirsch, A. (2014). Neoadjuvant chemotherapy for breast cancer: any progress?. *The Lancet Oncology*, *15*(2), 131-132.

Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., ... & Von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *The Lancet*, *384*(9938), 164-172.

Cosar, R., Sut, N., Ozen, A., Tastekin, E., Topaloglu, S., Cicin, I., ... & Uzal, M. C. (2022). Breast cancer subtypes and prognosis: Answers to subgroup classification questions, identifying the worst subgroup in our single-center series. *Breast Cancer: Targets and Therapy*, 259-280.

Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015). Breast cancer intrinsic subtype classification, clinical use and future trends. *American journal of cancer research*, *5*(10), 2929.

De Lena, M., Zucali, R., Viganotti, G., Valagussa, P., & Bonadonna, G. (1978). Combined chemotherapy-radiotherapy approach in locally advanced (T 3b-T 4) breast cancer. *Cancer chemotherapy and pharmacology*, *1*, 53-59.

Dumitru, A., Procop, A., Iliesiu, A., Tampa, M., Mitrache, L., Costache, M., ... & Cirstoiu, M. (2015). Mucinous breast cancer: a review study of 5 year experience from a hospital-based series of cases. *Maedica*, *10*(1), 14.

El-Hawary, A. K., Abbas, A. S., Elsayed, A. A., & Zalata, K. R. (2012). Molecular subtypes of breast carcinoma in Egyptian women: clinicopathological features. *Pathology-Research and Practice*, *208*(7), 382-386.

Faneyte, I. F., Schrama, J. G., Peterse, J. L., Remijnse, P. L., Rodenhuis, S., & Van de Vijver, M. J. (2003). Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. *British journal of cancer*, *88*(3), 406-412.

Feig, B. W., Berger, D. H., & Fuhrman, G. M. (Eds.). (2006). *The MD Anderson surgical oncology handbook*. Lippincott Williams & Wilkins.

Galli, G., Bregni, G., Cavalieri, S., Porcu, L., Baili, P., Hade, A., ... & Di Cosimo, S. (2017). Neoadjuvant chemotherapy exerts selection pressure towards luminal phenotype breast cancer. *Breast Care*, *12*(6), 391-394.

Globogan, The Global Cancer Observatory - All Rights Reserved, December, 2020.

Göttlicher, M., Heck, S., & Herrlich, P. (1998). Transcriptional cross-talk, the second mode of steroid hormone receptor action. *Journal of molecular medicine*, *76*, 480-489.

Guarneri, V., Broglio, K., Kau, S. W., Cristofanilli, M., Buzdar, A. U., Valero, V., ... & Gonzalez-Angulo, A. M. (2006). Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. *Journal of clinical oncology*, *24*(7), 1037-1044.

Grimm, S. L., Hartig, S. M., & Edwards, D. P. (2016). Progesterone receptor signaling mechanisms. *Journal of molecular biology*, *428*(19), 3831-3849.

He, Y., Zhang, J., Chen, H., Zhou, Y., Hong, L., Ma, Y., ... & Tong, Z. (2023). Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients. *Frontiers in Surgery*, *9*, 1037215.

Hirata, T., Shimizu, C., Yonemori, K., Hirakawa, A., Kouno, T., Tamura, K., ... & Fujiwara, Y. (2009). Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. *British journal of cancer*, *101*(9), 1529-1536.

Hoefnagel, L. D., van de Vijver, M. J., Van Slooten, H. J., Wesseling, P., Wesseling, J., Westenend, P. J., ... & van Diest, P. J. (2010). Receptor conversion in distant breast cancer metastases. *Breast cancer research*, *12*(5), 1-9.

Improta-Brears, T., Whorton, A. R., Codazzi, F., York, J. D., Meyer, T., & McDonnell, D. P. (1999). Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. *Proceedings of the National Academy of Sciences*, *96*(8), 4686-4691.

Jin, X., Jiang, Y. Z., Chen, S., Yu, K. D., Shao, Z. M., & Di, G. H. (2015). Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. *Oncotarget*, *6*(11), 9600.

Jinyan Du.2012.ErbB/HER Signaling.http://c.biomart.cn/cst cellsignaling/node/176

Jones, R. L., Salter, J., A'Hern, R., Nerurkar, A., Parton, M., Reis-Filho, J. S., ... & Dowsett, M. (2009). The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. *Breast cancer research and treatment*, *116*, 53-68.

Kahlert, S., Nuedling, S., Van Eickels, M., Vetter, H., Meyer, R., & Grohé, C. (2000). Estrogen receptor α rapidly activates the IGF-1 receptor pathway. *Journal of Biological Chemistry*, *275*(24), 18447-18453.

Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., ... & Singletary, S. E. (1999). Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. *Journal of Clinical Oncology*, *17*(2), 460-460.

Lakhani, S. R., Audretsch, W., Cleton-Jensen, A. M., Cutuli, B., Ellis, I., Eusebi, V., ... & Rutgers, E. (2006). The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?. *European journal of cancer*, *42*(14), 2205-2211.

Lamont, E. B., Herndon, J. E., Weeks, J. C., Henderson, I. C., Earle, C. C., Schilsky, R. L., & Christakis, N. A. (2006). Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). *Journal of the National Cancer Institute*, *98*(18), 1335-1338.

Levin, E. R. (2005). Integration of the extranuclear and nuclear actions of estrogen. *Molecular endocrinology*, *19*(8), 1951-1959.

Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., ... & Pusztai, L. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *Journal of clinical oncology*, *26*(8), 1275-1281.

Lindberg, M.K.; Rare, S.M.; Skrtic, S.; Gao, H.; Dahlman-Wright, K.; Gustafsson, J.-Å.; Ohlsson, C. (2003). Estrogen Receptor (ER)-Reduces ER-Regulated Gene Transcription, Supporting a "Ying Yang" Relationship between ER and ER in Mice. Mol. Endocrinol., 17, 203–208.

Li, C., Fan, H., Xiang, Q., Xu, L., Zhang, Z., Liu, Q., & Cui, Y. (2019). Prognostic value of receptor status conversion following neoadjuvant chemotherapy in

breast cancer patients: a systematic review and meta-analysis. *Breast Cancer Research and Treatment*, *178*, 497-504.

Li, P., Liu, T., Wang, Y., Shao, S., Zhang, W., Lv, Y., ... & Wang, Z. (2013). Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer. *Clinical Breast Cancer*, *13*(1), 53-60.

Lim, S. K., Lee, M. H., Park, I. H., You, J. Y., Nam, B. H., Kim, B. N., ... & Lee, E. S. (2016). Impact of molecular subtype conversion of breast cancers after neoadjuvant chemotherapy on clinical outcome. *Cancer research and treatment: official journal of Korean Cancer Association*, *48*(1), 133-141.

Lösel, Ralf; Wehling, Martin.(2003). Nongenomic actions of steroid hormones. *Nature reviews Molecular cell biology*, 4.1: 46-55.

Malhotra, G. K., Zhao, X., Band, H., & Band, V. (2010). Histological, molecular and functional subtypes of breast cancers. *Cancer biology & therapy*, *10*(10), 955-960.

Marchiò, C., Maletta, F., Annaratone, L., & Sapino, A. (2015). The perfect pathology report after neoadjuvant therapy. *Journal of the National Cancer Institute Monographs*, *2015*(51), 47-50.

Matsubara, N., Mukai, H., Masumoto, M., Sasaki, M., Naito, Y., Fujii, S., & Wada, N. (2014). Survival outcome and reduction rate of Ki-67 between pre-and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. *Breast cancer research and treatment*, *147*, 95-102.

Mauri, D., Pavlidis, N., & Ioannidis, J. P. (2005). Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. *Journal of the National Cancer Institute*, *97*(3), 188-194.

Mittendorf, E. A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K. K., Dawood, S., ... & Gonzalez-Angulo, A. M. (2009). Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. *Clinical Cancer Research*, *15*(23), 7381-7388.

Najafi B, Anvari S, Roshan ZA. (2013). Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2002 in Iran. Asian Pac J Cancer Prev, 14, 5811-16.

Neubauer, Hans, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). *Anticancer research*, 2008, 28.3B: 1797-1804.

Niikura, N., Tomotaki, A., Miyata, H., Iwamoto, T., Kawai, M., Anan, K., ... & Tokuda, Y. (2016). Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. *Annals of oncology*, *27*(3), 480-487.

Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., ... & Gustafsson, J. Å. (2001). Mechanisms of estrogen action. *Physiological reviews*, *81*(4), 1535-1565.

Olayioye, M. A. (2001). Intracellular signaling pathways of ErbB2/HER-2 and family members. *Breast cancer research*, *3*(6), 1-5.

Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. *Clinical medicine & research*, *7*(1-2), 4-13.

Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., Gómez-Valles, F. O., & Ramírez-Valdespino, C. A. (2022). Subtypes of breast cancer. *Breast Cancer [Internet]*.

Özdemir, Ö., Zengel, B., Çavdar, D. K., Yılmaz, C., & Durusoy, R. (2022). Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients. *European Journal of Breast Health*, *18*(2), 167.

Parise, C. A., & Caggiano, V. (2014). Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. *Journal of cancer epidemiology*, *2014*.

Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. *CA: a cancer journal for clinicians*, *55*(2), 74-108.

Parinyanitikul, N., Lei, X., Chavez-MacGregor, M., Liu, S., Mittendorf, E. A., Litton, J. K., ... & Gonzalez-Angulo, A. M. (2015). Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. *Clinical breast cancer*, *15*(2), 153-160.

Paruthiyil, S.; Parmar, H.; Kerekatte, V.; Cunha, G.R.; Firestone, G.L.; Leitmant, D.C.(2004). Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest. Cancer Res., 64, 423–428

Pelizzari, G., Gerratana, L., Basile, D., Fanotto, V., Bartoletti, M., Liguori, A., ... & Puglisi, F. (2019). Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. *Cancer Treatment Reviews*, *72*, 7-14.

Perou, C. M., Sørlie, T., Eisen, M. B., Van De Rijn, M., Jeffrey, S. S., Rees, C. A., ... & Botstein, D. (2000). Molecular portraits of human breast tumours. *nature*, *406*(6797), 747-752.

Pierga, J. Y., Mouret, E., Laurence, V., Dieras, V., Savigioni, A., Beuzeboc, P., ... & Pouillart, P. (2003). Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response. *European journal of cancer*, *39*(8), 1089-1096.

Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001). The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. *Endocrine-related cancer*, *8*(1), 11-31.

Razandi, M., Pedram, A., Park, S. T., & Levin, E. R. (2003). Proximal events in signaling by plasma membrane estrogen receptors. *Journal of Biological Chemistry*, *278*(4), 2701-2712.

Razandi, M., Pedram, A., Greene, G. L., & Levin, E. R. (1999). Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. *Molecular endocrinology*, *13*(2), 307-319.

Rose, D. P., & Davis, T. E. (1980). Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. *Cancer Research*, *40*(11), 4043-4047.

Rumack CM, Wilson SR, Charboneau JW. (1991). Ultrasound Diagnostic. *Mosby Year Book, St. Louis, MO, USA*,145-177.

Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J., Klijn, J. G., ... & Martens, J. W. (2008). Subtypes of breast cancer show preferential site of relapse. *Cancer research*, *68*(9), 3108-3114.

Su, Y., Zheng, Y., Zheng, W., Gu, K., Chen, Z., Li, G., ... & Shu, X. O. (2011). Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. *BMC cancer*, *11*, 1-11.

Surveillance Research Program, National Cancer Institute. Breast Cancer 5-year age adjusted incidence rates, 2016-2020. Accessed on April 21, 2023. https://seer.cancer.gov/explorer/, 2023.

Schwartz, G. F., Hortobagyi, G. N., Masood, S., Palazzo, J., Holland, R., & Page, D. C. (2004). Proceedings of the consensus conference on neoadjuvant

chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA. *Human pathology*, *35*, 781-784.

Tacca, O., Penault-Llorca, F., Abrial, C., Mouret-Reynier, M. A., Raoelfils, I., Durando, X., ... & Chollet, P. (2007). Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. *The oncologist*, *12*(6), 636-643.

Van de Ven, S., Smit, V. T. H. B. M., Dekker, T. J. A., Nortier, J. W. R., & Kroep, J. (2011). Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. *Cancer treatment reviews*, *37*(6), 422-430.

Viale, G. (2012). The current state of breast cancer classification. *Annals of oncology*, *23*, x207-x210.

Widodo, I., Dwianingsih, E. K., Triningsih, E., Utoro, T., & Soeripto, S. (2014). Clinicopathological features of Indonesian breast cancers with different molecular subtypes. *Asian Pacific Journal of Cancer Prevention*, *15*(15), 6109-6113.

Wu, Y. T., Li, X., Lu, L. J., Gan, L., Dai, W., Shi, Y. L. & Kong, L. Q. (2018). Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients. *Journal of biomedical research*, *32*(3), 191.

Wu, J. Y., Chen, W. G., Chen, X. S., Huang, O., He, J. R., Zhu, L., ... & Shen, K. W. (2014). Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy. *Molecular and Clinical Oncology*, *2*(6), 997-1002.

Yang, L., Zhong, X., Pu, T., Qiu, Y., Ye, F., & Bu, H. (2018). Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. *World Journal of Surgical Oncology*, *16*(1), 1-9.

Yoshida, A., Hayashi, N., Suzuki, K., Takimoto, M., Nakamura, S., & Yamauchi, H. (2017). Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. *Journal of Surgical Oncology*, *116*(8), 1021-1028.

Zhang, N., Moran, M. S., Huo, Q., Haffty, B. G., & Yang, Q. (2011). The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer investigation, 29(9), 594-598.

Zhao, Y., Dong, X., Li, R., Ma, X., Song, J., Li, Y., & Zhang, D. (2015). Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. *OncoTargets and therapy*, 1511-1521.

Zhao, Y., Wang, X., Huang, Y., Zhou, X., & Zhang, D. (2019). Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy. *Cancer management and research*, 5677-5690.